Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.61 |
| ▸ | TYK2 | P29597 | 9/20 | 0.61 |
| ▸ | JAK1 | P23458 | 8/20 | 0.61 |
| ▸ | JAK3 | P52333 | 8/20 | 0.61 |
| ▸ | FLT3 | P36888 | 15/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
| ▸ | CCND3 | P30281 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608214 | 0.84 | JAK2 (0.64) | JAK2TYK2JAK1JAK3FLT3 | |
| SCHEMBL29527869 | 0.83 | JAK2 (0.65) | JAK2TYK2JAK1JAK3FLT3 | |
| SCHEMBL29608225 | 0.82 | JAK2 (0.75) | JAK2TYK2JAK1JAK3FLT3 | |
| SCHEMBL24664433 | 0.82 | JAK2 (0.75) | JAK2TYK2JAK1JAK3FLT3 | |
| SCHEMBL22852642 | 0.81 | JAK2 (0.69) | JAK2TYK2JAK1JAK3FLT3 | |
| SCHEMBL24664434 | 0.80 | JAK2 (0.71) | JAK2TYK2JAK1JAK3FLT3 | |
| SCHEMBL29607219 | 0.80 | JAK2 (0.71) | JAK2TYK2JAK1JAK3FLT3 | |
| Hydrochloric Acid SCHEMBL31460911 | 0.79 | JAK2 (0.69) | JAK2TYK2JAK1JAK3FLT3 | |
| SCHEMBL29425676 | 0.79 | JAK2 (0.58) | JAK2TYK2JAK1JAK3FLT3 | |
| SCHEMBL29741634 | 0.79 | JAK2 (0.68) | JAK2TYK2JAK1JAK3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423750-B | 2, 4-Disubstituted pyrimidine derivative, preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20220298140-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-114423750-A | 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298140-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | JAK2, FLT3, JAK1 | JAK2 1/4885TYK2 15/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.